



BUREAU OF NATUROPATHIC MEDICINE
1625 North Market Blvd., Suite S-209
Sacramento, CA 95834
(916) 574-7991 – Office / (916) 574-8645 - FAX



NATUROPATHIC FORMULARY ADVISORY COMMITTEE
Meeting Minutes
August 29, 2006

**COMMITTEE MEMBERS
PRESENT:**

Peter Wannigman, Naturopathic Doctor
(Chairman)
Soram Khalsa, Medical Doctor (Vice
Chair)
Mary Hardy, Medical Doctor
Cynthia Watson, Medical Doctor
Trevor Holly Cates, Naturopathic Doctor
Michael Traub, Naturopathic Doctor
Paul Mittman, Naturopathic Doctor
Arthur Presser, Pharmacist
Larry Woodhouse, Pharmacist
Tonya Blood
Norine Marks
Linda Brown

STAFF PRESENT:

I. Call to Order and Roll Call

Chairman Wannigman called the meeting to order. Roll call was taken and a quorum was present.

II. Approval of the July 23, 2006 Meeting Minutes

Dr. Hardy made a motion that the minutes be approved as written. Dr. Khalsa seconded the motion. Roll was called and the minutes were approved as written.

III. Chairperson's Report

Dr. Wannigman made a statement that it was very important for the Committee to collaborate with the project as a group and that the recommendations be unanimous in their approvals. It is important that the recommendations that move forward have full consensus.

IV. Discussion and Approval of Rationale for ND Prescribing

Dr. Mittman and Dr. Cates worked on this together. Dr. Mittman emailed a published document from the Textbook on Natural Medicine to the members of the Committee which was published in 2006. The document was from a chapter entitled The Hierarchy of Healing, under the heading The Therapeutic Order, starting on page 18 of the document. Dr. Mittman stated that maybe that was better than trying to create the Committee's own rationale. It was determined to use the document in the appendix, but extract some pertinent statements from it for the report. Dr. Mittman will complete the portion for the report and distribute to everyone by Friday.

V. Report from Dr. Khalsa

a. Discussion with CMA regarding Committee recommendations

Dr. Khalsa reported that he spoke with Sandra Bressler from the California Medical Association. He asked Ms. Bressler about the expanded formulary that the Committee was recommending and what the CMA's position would be. Ms. Bressler stated that the CMA will not allow any health professionals to prescribe other than MDs. CMA would strongly oppose any increase in independent prescribing rights for NDs.

b. Discussion with SCPIE Regarding Malpractice Insurance Surcharge for Supervising an ND

Dr. Khalsa reported that he spoke with Dr. Mitch Karlin, who is a former President of the Medical Board and now is the Chairman of SCPIE, a large malpractice insurance company in Southern California. Dr. Karlin stated that SCPIE is not interested in insuring any MD for supervision of an ND. Dr. Khalsa stated that he has also been trying to get information from the Doctor's Company about whether they would cover an MD for supervising an ND. The Doctors Company wanted everything in writing and Dr. Khalsa has been busy sending them faxes and emails. They promised to give him an answer in time for the meeting but they did not send him anything.

VI. Discussion, Review, and Approval of IV Formulary

The committee discussed the IV formulary and whether changes needed to be made to what had been approved. It was tabled for the next meeting.

VII. Discussion and Approval of Recommendation of Additional Formulary for NDs Meeting Current (48 hour) Prescribing Requirements

Dr. Khalsa suggested that the Committee should re-think their recommendations and that a smaller inclusionary formulary would be a better recommendation to come out of the Committee.

Dr. Watson agreed with a smaller inclusionary formulary and also stated that the Committee should take another look at the IV formulary.

Tonya added that Director Zettel also liked the idea of an inclusionary list, rather than an exclusionary list.

Dr. Hardy commented that the Committee needed to be very conservative in its recommendations so as not to engender a strong backlash and active resistance. Points to be made are that physician supervision is impossible because of the lack of malpractice

coverage and the lack of available physicians to do oversight – therefore there should be some prescriptive authority for NDs without supervision. The Committee needs to make very reasonable recommendations.

Dr. Presser agreed that Dr. Watson's inclusionary list looked more like "evolution rather than revolution." He suggested perhaps NDs could prescribe for a list of conditions.

Dr. Traub thanked Dr. Khalsa, Dr. Watson, and everyone for the work they had done since the last meeting. He stated that the Committee's discussions have evolved to where they are now looking at the recommendations with a good deal of realism in face of what legislation changes they want to recommend. He stated he feels good about the direction that the revised inclusionary formulary is going and feels that vaccines should be added to it.

Tonya emphasized that the Bureau wants everyone on the Committee to be comfortable with the recommendations.

Dr. Mittman stated that the Committee should present a reasonable, defensible, objectively based list and he stated that the inclusionary list meets that criteria.

Dr. Wannigman stated that the inclusionary list does a good job of covering everyday primary care medical needs.

The Committee discussed going forward with the smaller inclusionary list rather than the exclusionary list they had previously approved.

Dr. Traub made a motion to approve the inclusionary list, with the following changes:

- 1) Exclude oral amino glycosides.
- 2) Include neomycin.
- 3) Revise Opioids to say Schedule III, IV, and V only.
- 4) Exclude endocrines.
- 5) Include vaccines.
- 6) Include IV nutritional therapy categories I, II, III, IV, and VIII.
- 7) Exclude biologicals and botanicals unless they are the subject of an IRB-approved study.
- 8) Make DMSO, IRB-approved study only.
- 9) Make category IV "electrolytes and diluents."

Dr. Watson seconded the motion. The motion was approved.

VIII. Review of Draft Report

The committee briefly reviewed the draft report and made suggestions for revisions.

IX. Future Meeting Date

The committee will meet again on Monday, September 11, 2006 at 6:00 p.m.

X. Public Comment

There was no public comment.

XI. Adjournment

The meeting was adjourned.